

1 **Relationship between astrocyte reactivity, using novel <sup>11</sup>C-BU99008 PET, and glucose metabolism, grey**  
2 **matter volume and amyloid load in cognitively impaired individuals**

3 Nicholas R Livingston, MSc<sup>1\*</sup>; Valeria Calsolaro, MD, PhD<sup>1\*</sup>; Rainer Hinz, PhD<sup>2</sup>; Joseph Nowell, MSc<sup>1</sup>; Sanara  
4 Raza, MSc<sup>1</sup>; Steve Gentleman, PhD<sup>1</sup>; Robin J Tyacke, PhD<sup>1</sup>; Jim Myers, PhD<sup>1</sup>; Ashwin V Venkataraman, MD,  
5 PhD<sup>1</sup>; Robert Perneczky, MD, PhD<sup>3,4,5,6</sup>; Roger N Gunn, PhD<sup>7,8</sup>; Eugenii A Rabiner, MBBCh, FCPsych SA<sup>7,8</sup>;  
6 Christine A Parker, PhD<sup>9</sup>; Philip S Murphy, PhD<sup>9</sup>; Paul B Wren, PhD<sup>9</sup>; David J Nutt, MD, PhD, FRCP, FMedSci<sup>1</sup>;  
7 Paul M Matthews, MD, DPhil, FRCP, FMedSci<sup>1,10</sup>; Paul Edison, MBBS, PhD, FRCP<sup>1Ψ</sup>

8 \* Both authors contributed equally to the manuscript

9

10

11 1 - Dept of Brain Sciences, Imperial College London, London, United Kingdom

12 2 - Wolfson Molecular Imaging Centre, University of Manchester, UK

13 3 - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany

14 4 - German Centre for Neurodegenerative Disorders (DZNE) Munich, Germany

15 5 - Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

16 6 - Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK

17 7 - Invicro, London, United Kingdom

18 8 - King's College London, London, United Kingdom

19 9 - GlaxoSmithKline, Stevenage, United Kingdom

20 10 - UK Dementia Research Institute at Imperial College London

21

22 <sup>Ψ</sup> Corresponding author:

23 Dr Paul Edison, MD, MRCP, PhD, FRCP, FRCPI,

24 Clinical Senior Lecturer, Imperial College London,

25 Department of Brain Sciences, Faculty of Medicine  
~~None of the preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.~~

26 1st Floor, B Block  
27 Hammersmith Hospital Campus,  
28 Du Cane Road, London, W12 0NN  
29 Tel: +442083833725 Fax: +442033134320  
30 E-mail: paul.edison@imperial.ac.uk

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 **Abstract**

58

59 *Post mortem* neuropathology suggests that astrocyte reactivity may play a significant role in neurodegeneration  
60 in Alzheimer's disease. We explored this *in vivo* using multimodal PET and MRI imaging. Twenty subjects (11  
61 older, cognitively impaired subjects and 9 age-matched healthy controls) underwent brain scanning using the  
62 novel reactive astrocyte PET tracer <sup>11</sup>C-BU99008, <sup>18</sup>F-FDG and <sup>18</sup>F-florbetaben PET, and T1-weighted MRI.  
63 Differences between cognitively impaired subjects and healthy controls in voxel-wise levels of astrocyte  
64 reactivity, glucose metabolism and grey matter volume were explored, and their relationship to each other was  
65 assessed using Biological Parametric Mapping (BPM). Aβ-positive cognitively impaired subjects showed greater  
66 brain astrocyte reactivity, except in the temporal lobe, with further increased astrocyte reactivity in Mild Cognitive  
67 Impairment compared to Alzheimer's subjects in the cingulate cortices. BPM correlations revealed regions which  
68 showed reduced <sup>11</sup>C-BU99008 uptake in Aβ-positive cognitively impaired subjects, such as the temporal lobe,  
69 also showed reduced <sup>18</sup>F-FDG uptake and grey matter volume. BPM analysis also revealed a regionally-dynamic  
70 relationship between astrocyte reactivity and amyloid uptake: increased amyloid load in cortical association areas  
71 of the temporal lobe and cingulate cortices was associated with *reduced* astrocyte reactivity, whilst increased  
72 amyloid uptake in primary motor and sensory areas (in which amyloid load occurs later) was associated with  
73 *increased* astrocyte reactivity. These novel observations add to the hypothesis that while astrocyte reactivity may  
74 be triggered by early Aβ-deposition, sustained pro-inflammatory astrocyte reactivity with greater amyloid  
75 deposition may lead to astrocyte dystrophy and amyloid-associated neuropathology such as grey matter atrophy  
76 and glucose hypometabolism.

77

78

79

80

81

82

83

84

## 85 1. Introduction

86 Astrocytes are integral to normal brain function, playing important roles in neurogenesis, synaptogenesis, control  
87 of blood-brain barrier permeability and maintaining extracellular homeostasis<sup>1</sup>. In Alzheimer's disease (AD),  
88 astrocytes can assume a reactive phenotype in which they become hypertrophic with the upregulation of glial  
89 fibrillary acidic protein (GFAP)<sup>2</sup>. Astrocyte reactivity associated with amyloid beta (A $\beta$ ) plaques is believed to  
90 have a neuroprotective role in pre-symptomatic and early AD<sup>3</sup> through expression of proteases involved in the  
91 enzymatic cleavage and removal of A $\beta$ <sup>4</sup>. However, with higher levels of A $\beta$ , astrocyte reactivity can produce  
92 neurotoxic reactive oxygen species and inflammatory cytokines<sup>5</sup>. Astrocytes in AD also can lose normal  
93 neuroprotective capabilities as they become dystrophic with the progression of AD pathology<sup>6, 7</sup>.

94

95 Glucose hypometabolism, measured using <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET, and brain atrophy, measured  
96 using MRI, were two of the earliest neuroimaging markers of neurodegeneration developed for AD<sup>8</sup>. By  
97 contributing to synaptic loss and neurodegeneration, pro-inflammatory and dystrophic astroglia may be associated  
98 with accelerated grey matter atrophy<sup>9</sup>. Astrocytes are also necessary for metabolic support of neuronal activity<sup>10</sup>,  
99 so AD related changes in astrocytes might contribute directly to the brain glucose hypometabolism characteristic  
100 of AD<sup>8</sup>.

101

102 The novel PET tracer <sup>11</sup>C-BU99008 has high specificity and selectivity for binding sites of type-2 imidazoline  
103 receptors (I<sub>2</sub>-BS), which are expressed primarily within astrocytes and are up-regulated with reactivity<sup>11</sup>. This  
104 tracer thus allows the study of astrocyte reactivity *in vivo*<sup>12-17</sup>. Pathologically increased <sup>11</sup>C-BU99008 PET signal  
105 recently has been demonstrated in neurodegenerative disorders including AD<sup>18</sup> and Parkinson's disease<sup>19</sup>.  
106 Currently, the only available PET tracer which can measure astrocyte reactivity *in vivo* is <sup>11</sup>C-deuterium-L-  
107 deprenyl (<sup>11</sup>C-DED)<sup>20, 21</sup>. However, this tracer binds to monoamine oxidase-B (MAO-B), which is not  
108 significantly elevated in late stage A $\beta$ -deposition. The increased sensitivity of <sup>11</sup>C-BU99008 over <sup>11</sup>C-DED to  
109 detect astrocyte reactivity has recently been demonstrated in a preclinical model of AD<sup>22</sup>, thus warranting its use  
110 through further study in this clinical population. The aim of this study was to evaluate the relationship between  
111 astrocyte reactivity, using <sup>11</sup>C-BU99008 PET, glucose metabolism, grey matter atrophy and A $\beta$ -deposition in  
112 cognitively impaired subjects with a clinical diagnosis of AD-related dementia or mild cognitive impairment  
113 (MCI).

## 114 2. Materials and Methods

115 We recruited 20 subjects for this pilot study. Ethical approval for this study was obtained from the local and  
116 regional Research Ethics Committee, whilst approval to administer radiotracers was obtained from the  
117 Administration of Radioactive Substances Advisory Committee (ARSAC) UK. The human biological samples  
118 sourced from participants were obtained ethically and their research use was in accordance with the terms of the  
119 informed consent.

120

### 121 2.1 Subjects

122 Subjects were recruited from memory clinics, research registries and advertisements. We included 11 cognitively  
123 impaired subjects with a clinical diagnosis of AD-related dementia or MCI (6 AD, 5 MCI; Mini-Mental Status  
124 Examination (MMSE) score [mean  $\pm$ SD] = 22.6  $\pm$ 4.1) and 9 age-matched healthy volunteers without a history of  
125 brain disease (MMSE score [mean  $\pm$ SD] = 29.1  $\pm$ 1.27). The inclusion criteria for cognitively impaired subjects  
126 included the ability to give informed consent, an MMSE score  $\geq$ 17 and at least 8 years of education. Exclusion  
127 criteria included contradictions to MRI and any evidence of significant small vessel or vascular disease on MRI.  
128 All subjects underwent medical and detailed cognitive assessments using the Repeatable Battery for the  
129 Assessment of Neuropsychological Status (RBANS), as well as  $^{11}\text{C}$ -BU99008,  $^{18}\text{F}$ -FDG and  $^{18}\text{F}$ -florbetaben PET  
130 and T1-weighted structural MRI. A $\beta$ -positivity was defined by using a whole brain uptake cut-off of 1.43<sup>23</sup>.

131

### 132 2.2 Image acquisition

133 All image acquisition was performed at the Invicro Centre for Imaging Sciences in London, UK. MRI images  
134 were acquired using either a 3 Tesla Magnetom Trio or Verio (Siemens Healthcare Sector, Erlangen, Germany)  
135 with a 32-receiver channel head matrix coil. All PET imaging was performed on a Siemens Truepoint PET/CT  
136 scanner.

#### 137 2.2.1 MRI

##### 138 2.2.1 Structural MRI

139 All subjects underwent a sagittal T1-weighted MPRAGE, acquired with TR=2400 ms, TE=3.06 ms, flip angle=9°,  
140 TI=900 ms, matrix=[256 x 246], a 1 mm isotropic voxel size, anteroposterior phase encoding direction, IPAT  
141 factor 2 and a symmetric echo.

142

## 143 **2.2.2 PET**

### 144 **2.2.2.1 <sup>11</sup>C-BU99008 PET**

145 All subjects underwent <sup>11</sup>C-BU99008 PET scanning to assess astrocyte reactivity in the brain. <sup>11</sup>C-BU99008 was  
146 synthesised on site. An initial CT scan was acquired for attenuation correction of the PET images, before a mean  
147 activity of 330 (±30) MBq <sup>11</sup>C-BU99008 in 20ml normal saline was injected into the antecubital vein. Dynamic  
148 emission <sup>11</sup>C-BU99008 PET images were acquired over 120 minutes and rebinned into 29 timeframes: 8x15s,  
149 3x60s, 5x120s, 5x300s, and 8x600s. All subjects had arterial blood sampled continuously for the first 15 minutes,  
150 with twelve additional samples taken at 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, and 100 minutes after injection.  
151 A gamma counter was used to measure radioactivity in the whole blood and plasma for each sample. Reverse-  
152 phase high-performance liquid chromatography was used to evaluate metabolism of <sup>11</sup>C-BU99008 by calculating  
153 the relative proportions of parent tracer and metabolites in the blood. Parametric images (Impulse Response  
154 Function at 120 minutes (IRF-120)) of <sup>11</sup>C-BU99008 was generated using spectral analysis. This was performed  
155 using MICK-PM (Modelling, Input Functions and Compartmental Kinetics Parametric Map) software (available  
156 on request from Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK).

157

### 158 **2.2.2.2 <sup>18</sup>F-FDG and <sup>18</sup>F-florbetaben PET**

159 All subjects also underwent <sup>18</sup>F-FDG and <sup>18</sup>F-florbetaben PET scanning to assess glucose metabolism and Aβ-  
160 deposition in the brain, respectively. Subjects received a target dose of 185 MBq <sup>18</sup>F-FDG and 236.4 (±6.8) MBq  
161 <sup>18</sup>F-florbetaben as single intravenous boluses in the respective scanning sessions. For <sup>18</sup>F-FDG scans, PET  
162 acquisition commenced 30 minutes after tracer injection, and the scans were acquired for 30 minutes. Using  
163 MICKPM, activity over the last 30 minutes was averaged, resulting in a 3D 30-60min <sup>18</sup>F-FDG add image. For  
164 <sup>18</sup>F-florbetaben scans, PET acquisition commenced 90 minutes after tracer administration and the subjects were  
165 scanned for 30 minutes. Activity over the 30-minute acquisition period was averaged, resulting in a 3D 90-120min  
166 <sup>18</sup>F-florbetaben add image.

## 167 **2.3 Image processing**

168 MRI and PET images were pre-processed using SPM12 (Wellcome centre for human neuroimaging, UCL,  
169 London, UK) in MATLAB (v2014a). 3D PET data was co-registered to the structural MRI of each subject. The  
170 structural MRI was segmented into grey matter (GM), white matter (WM) and CSF, and the GM and WM maps  
171 were used to generate a study-specific template using diffeomorphic anatomical registration through  
172 exponentiated lie algebra (DARTEL)<sup>24</sup>. The DARTEL flow fields were then used to normalise each of the  
173 coregistered PET images and GM maps to MNI space and an 8mm FWHM Gaussian kernel was used to smooth  
174 the data. Tracer uptake for <sup>11</sup>C-BU99008 PET was calculated through spectral analysis (IRF-120min). Tracer  
175 uptake for <sup>18</sup>F-FDG and <sup>18</sup>F-florbetaben PET was evaluated using the standardised uptake value ratio (SUVR) and  
176 the Hammers atlas<sup>25</sup>, referenced to the pons grey & white matter and the cerebellar grey matter, respectively. This  
177 was done by dividing the cerebral cortical <sup>18</sup>F-FDG and <sup>18</sup>F-florbetaben mean images by the uptake value of the  
178 relevant reference region, which had been calculated in Analyze 11.0 (developed by the Biomedical Imaging  
179 Resource (BIR) at the mayo clinic). This resulted in smoothed normalised <sup>18</sup>F-FDG, <sup>18</sup>F-florbetaben, <sup>11</sup>C-  
180 BU99008 and GM voxel-based morphometry (VBM) images that were used to assess glucose metabolism, A $\beta$   
181 deposition, astrocyte reactivity and grey matter atrophy patterns, respectively. This was done through voxel-wise  
182 statistical parametric mapping (SPM) and biological parametric mapping (BPM) analysis.

183

## 184 **2.4 SPM analysis**

185 Voxel-level SPM analysis was performed in order to better characterise the spatial distribution of tracer uptake  
186 difference between the cognitively impaired subjects and the healthy controls. The smoothed normalised <sup>11</sup>C-  
187 BU99008 IRF-120 parametric maps, 30-60min <sup>18</sup>F-FDG add images, 90-120min <sup>18</sup>F-florbetaben add images and  
188 VBM GM images of all subjects were entered into 4 separate two-sample Student's t-test in SPM12 (2-tailed).

189

## 190 **2.5 BPM and ROI correlation analysis**

191 In order to assess the neuroanatomical relationship between <sup>11</sup>C-BU99008 binding and glucose metabolism, A $\beta$   
192 deposition and GM atrophy, BPM and ROI correlation analysis was performed. For the ROI correlations, subject-  
193 specific object maps were created from the Hammers atlas<sup>25, 26</sup> and were used to sample the ROI radioactivity  
194 concentration for the 3 normalised (not smoothed) PET images, as well as the ROI volume of the VBM images.

195 The ROIs included the frontal lobe, temporal lobe, medial temporal lobe, parietal lobe, occipital lobe, anterior  
196 cingulate, posterior cingulate and the whole brain (made up of the 4 lobes and the cingulate). Correlation between  
197 each of the 4 imaging measures in each of the four lobes and whole brain for A $\beta$ -positive patients was calculated  
198 using Pearson's correlation coefficient in SPSS (v26, released 2019). For the BPM correlations, Z-score maps for  
199 each of the 4 imaging modalities were created. These represent tracer uptake and GM atrophy patterns relative to  
200 the healthy control's mean and standard deviation for each version subject on a voxel-level basis, calculated with the  
201 following formulae:

$$202 \quad Zmap \text{ of } ^{11}\text{C-BU99008} = \frac{\text{Patient } ^{11}\text{C-BU99008} - \text{mean of healthy controls } ^{11}\text{C-BU99008}}{\text{SD of healthy controls } ^{11}\text{C-BU99008}}$$

$$203 \quad Zmap \text{ of } ^{18}\text{F-FDG} = \frac{\text{Patient } ^{18}\text{F-FDG} - \text{mean of healthy controls } ^{18}\text{F-FDG}}{\text{SD of healthy controls } ^{18}\text{F-FDG}}$$

$$204 \quad Zmap \text{ of } ^{18}\text{F-florbetaben} = \frac{\text{Patient } ^{18}\text{F-florbetaben} - \text{mean of healthy controls } ^{18}\text{F-florbetaben}}{\text{SD of healthy controls } ^{18}\text{F-florbetaben}}$$

$$205 \quad Zmap \text{ of VBM GM} = \frac{\text{Patient VBM GM} - \text{mean of healthy controls VBM GM}}{\text{SD of healthy controls VBM GM}}$$

206 Voxel-level correlations between <sup>11</sup>C-BU99008 and the remaining three modalities were estimated for all patients  
207 using BPM<sup>27</sup>, an SPM toolbox that runs through MATLAB. Additional correlations were run on A $\beta$ -positive  
208 patients between <sup>11</sup>C-BU99008 and <sup>18</sup>F-FDG & VBM GM.

209

210

### 211 3. Results

212 All the healthy controls were A $\beta$ -negative, 7 of the patients were A $\beta$ -positive (4 AD, 3 MCI) and 4 patients were  
213 A $\beta$ -negative (2 AD, 2 MCI).

#### 214 3.1 Group-level SPM analysis

215 Two-sample t-tests in SPM contrasting A $\beta$ -positive patients and healthy controls showed distributions of  
216 differences in tracer uptake and grey matter volumes that were consistent with the ROI-analyses. A $\beta$ -positive  
217 patients had increased <sup>11</sup>C-BU99008 uptake particularly in the frontal and occipital lobes (Figure 1a), reduced <sup>18</sup>F-  
218 FDG uptake in the temporal, parietal and occipital lobes (Figure 1b), reduced grey matter volume in temporal  
219 regions, particularly the hippocampi (Figure 1c), and increased <sup>18</sup>F-florbetaben uptake in frontotemporal regions



220 (Figure 1d). An exploratory two-sample t-test comparing MCI and AD subjects showed increased  $^{11}\text{C-BU99008}$   
221 uptake in MCI patients, particularly in the frontal and temporal regions.

222

## 223 **3.2 Regional and Voxel-wise Correlations**

### 224 **3.2.1 $^{11}\text{C-BU99008}$ x $^{18}\text{F-FDG}$**

225 BPM analysis showed that reduced  $^{11}\text{C-BU99008}$  uptake was correlated with reduced  $^{18}\text{F-FDG}$  uptake,  
226 particularly in the temporal, parietal and frontal lobes. ROI correlations suggested the same directions for  
227 correlations, although none of the regions reached statistical significance frontal ( $r=0.202$ ,  $p=0.664$ ), occipital  
228 ( $r=0.264$ ,  $p=0.567$ ), temporal ( $r=0.567$ ,  $p=0.184$ ) and parietal ( $r=0.622$ ,  $p=0.135$ ) lobes, and the whole brain  
229 ( $r=0.478$ ,  $p=0.279$ ).

### 230 **3.2.2 $^{11}\text{C-BU99008}$ x VBM**

231 BPM analysis showed reduced  $^{11}\text{C-BU99008}$  uptake was correlated with reduced grey matter volume in the frontal  
232 and temporal lobes. ROI correlations showed the same correlation, showing strong correlations in the frontal  
233 ( $r=0.808$ ,  $p=0.028$ ), temporal ( $r=0.935$ ,  $p=0.002$ ), parietal ( $r=0.833$ ,  $p=0.020$ ) and occipital lobes ( $r=0.762$ ,  
234  $p=0.047$ ), as well as the whole brain ( $r=0.901$ ,  $p=0.006$ ).

### 235 **3.2.3 $^{11}\text{C-BU99008}$ x $^{18}\text{F-florbetaben}$**

236 BPM analysis described an inverse correlation of increased  $^{18}\text{F-florbetaben}$  uptake with reduced  $^{11}\text{C-BU99008}$   
237 uptake in regions such as the temporal lobe and the cingulate, whilst increased  $^{18}\text{F-florbetaben}$  uptake was  
238 positively correlated with increased  $^{11}\text{C-BU99008}$  uptake in primary motor and primary sensory areas. ROI  
239 analyses showed that reduced  $^{11}\text{C-BU99008}$  uptake was correlated with increased  $^{18}\text{F-florbetaben}$  uptake,  
240 particularly in the frontal ( $r=-0.780$ ,  $p=0.039$ ), temporal ( $r=-0.779$ ,  $p=0.039$ ), occipital ( $r=-0.911$ ,  $p=0.004$ ) lobe  
241 and the whole brain ( $r=-0.798$ ,  $p=0.032$ ).

242

243

244

245

#### 246 4. Discussion

247

248 In this study, we used the novel imidazoline receptor PET tracer  $^{11}\text{C}$ -BU99008 to test for evidence of a  
249 dynamic relationship between astrocyte reactivity and amyloid-associated neurodegeneration based on tissue  
250 hypometabolism and atrophy measured using  $^{18}\text{F}$ -FDG PET and structural MRI, respectively. We found evidence  
251 for increased astrocyte reactivity in A $\beta$ -positive patients, primarily in frontal, parietal and occipital regions. These  
252 increases were greater in MCI than AD patients. Regional correlational analyses showed that lower astrocyte  
253 reactivity in A $\beta$ -positive patients was associated with both glucose hypometabolism in the parietal, temporal and  
254 frontal lobes and grey matter atrophy in frontal and temporal lobes. However, analyses of regional differences in  
255 the relationships between PET markers of A $\beta$ -deposition and astrocyte reactivity displayed a striking  
256 heterogeneity; greater A $\beta$ -deposition was associated with increased astrocyte reactivity in primary motor and  
257 primary sensory cortical areas, but decreased astrocyte reactivity in temporal regions.

258

259  $^{11}\text{C}$ -BU99008 is a novel PET tracer that binds to I<sub>2</sub>-BS, expression of which is associated with astrocyte  
260 reactivity<sup>28,29</sup>. Brain I<sub>2</sub>-BS is upregulated with healthy aging<sup>30</sup>, and is further increased in AD<sup>31</sup>. The sensitivity  
261 and specificity of  $^{11}\text{C}$ -BU99008 to bind to I<sub>2</sub>-BS expressing reactive astrocytes has been further evidenced in a  
262 recent autoradiography study of AD brains where tracer uptake was greater compared to cognitively normal  
263 brains<sup>22</sup>. In line with this, we found cognitively impaired subjects showed increased  $^{11}\text{C}$ -BU99008 uptake  
264 compared to healthy controls, corroborating earlier studies with another PET marker of astrocyte reactivity,  $^{11}\text{C}$ -  
265 deuterium-L-deprenyl ( $^{11}\text{C}$ -DED)<sup>32</sup>. Additionally, we found increased  $^{11}\text{C}$ -BU99008 uptake in MCI subjects  
266 compared to AD subjects, particularly in the frontal lobe. Interestingly, another  $^{11}\text{C}$ -DED study also found  
267 increased uptake in the frontal lobe in A $\beta$ -positive MCI, but not AD, subjects compared to healthy controls<sup>20</sup>.  
268 Both these findings agree with the hypothesis that astrocyte reactivity is an early event in the progression of AD  
269 pathology, occurring in response to early amyloid deposition, which typically originates in the frontal lobe<sup>33</sup>. In  
270 the early stages, reactive astrocytes have a neuroprotective role, aiding in the clearance of A $\beta$ <sup>4</sup>. Further evidence  
271 of this hypothesis comes from a subsequent study that showed increased  $^{11}\text{C}$ -DED binding in autosomal dominant  
272 AD patients early in their disease progression<sup>34</sup>, primarily in temporal regions, another region involved in early  
273 A $\beta$  deposition<sup>35</sup>. In our cohort of A $\beta$ -positive MCI and AD subjects, we found lower  $^{11}\text{C}$ -BU99008 binding in the  
274 temporal lobe, which was associated with greater relative progression of amyloid-associated neuropathology, that

275 is glucose hypometabolism and grey matter atrophy. We propose this reduced  $^{11}\text{C}$ -BU99008 uptake in the  
276 temporal lobe region reflects astrocyte dystrophy<sup>36</sup>, brought about by an amyloid-induced chronic pro-  
277 inflammatory and neurotoxic astrocyte phenotype<sup>37</sup> and resulting in reduced glycolytic capacity and secondary  
278 impaired neuronal metabolism<sup>38</sup> or cell loss<sup>39, 40</sup>. Correlations between regional reductions in  $^{11}\text{C}$ -DED and  $^{18}\text{F}$ -  
279 FDG PET signals similar to those described here also were associated with regionally more advanced  $^{11}\text{C}$ -PIB  
280 PET pathology in a longitudinal study of people with autosomal dominant AD or MCI<sup>41</sup>. Interaction of A $\beta$  with  
281 reactive astrocytes has been proposed as a trigger for astrocytes to switch from a neuroprotective to a neurotoxic  
282 role.

283

284 There are obvious limitations to our study. First, only a small number of subjects were able to be imaged. While  
285 this is a pilot study, the explanatory power was enhanced by the design in which uptake of the three PET tracers  
286 and brain volume all were assessed in the same people. A second limitation was the cross-sectional design, which  
287 we acknowledge; however, *post mortem* pathology has the same limitation. Our results thus are better interpreted  
288 descriptively and as suggestive of a hypothetical model, rather than a strong, independent test. Nonetheless, the  
289 consistency of directions of effect observed in this study and the earlier  $^{11}\text{C}$ -DED PET studies<sup>20, 41</sup> provides  
290 compelling support for the model proposed. That is, astrocyte reactivity occurs in response to early A $\beta$ -deposition,  
291 aiding in the clearance of A $\beta$ , but following interactions with high levels of A $\beta$  the astrocytes become neurotoxic,  
292 contributing to reduced tissue activity and cell death that is associated with cognitive impairment. It also  
293 strengthens confidence in the earlier work, which otherwise suffers from uncertainties regarding the specificity of  
294 binding of  $^{11}\text{C}$ -DED in the brain<sup>20</sup>. Nonetheless,  $^{11}\text{C}$ -BU99008 can detect astrocyte reactivity with a greater  
295 sensitivity than  $^{11}\text{C}$ -DED<sup>22</sup>, especially amongst higher levels of amyloid load<sup>18, 42</sup>, and thus should be prioritised.

296

297 In conclusion, this study supports neuropathological observations arguing that astrocyte reactivity with amyloid-  
298 related neuropathology is dynamic<sup>2</sup>. We have demonstrated *in vivo* with the novel PET tracer  $^{11}\text{C}$ -BU99008 that  
299 astrocyte reactivity is increased in regions presumed to represent earlier stages of pathological progression with  
300 low A $\beta$ -deposition loads, and conversely relatively reduced in regions that show signs of more advanced disease  
301 progression with greater A $\beta$ -deposition and atrophy. In the absence of molecular imaging markers intrinsically  
302 discriminating different microglial activation phenotypes, our multi-modal imaging approach may allow relevant  
303 inferences to be made from the relative  $^{11}\text{C}$ -BU99008,  $^{18}\text{F}$ -FDG and  $^{18}\text{F}$ -florbetaben PET signals and brain volume

304 sensitive MRI measures. Future, larger, longitudinal studies are needed to further test this dynamic model and, if  
305 supported, interventions developed to arrest progression of the neurotoxic phenotypic transformation of astrocytes  
306 in AD.

307

### 308 **Acknowledgements**

309 The authors thank Invicro Centre for Imaging Sciences for the provision of <sup>11</sup>C-BU99008, scanning and blood  
310 analysis equipment. The authors also thank Piramal Life Sciences/Life Molecular Imaging for providing the <sup>18</sup>F-  
311 florbetaben and permission to acquire unlabelled florbetaben. We thank Dementia Platform UK (DPUK) and GSK  
312 for the generous funding for this project. This research was co-funded by the NIHR Imperial Biomedical Research  
313 Centre and was supported by the NIHR Imperial Clinical Research Facility. The views expressed are those of the  
314 authors and not necessarily those of NHS, the NIHR nor the Department of Health. P.E. was funded by the Medical  
315 Research Council and now by Higher Education Funding Council for England (HEFCE). He has also received  
316 grants from Alzheimer's Research, UK, Alzheimer's Drug Discovery Foundation, Alzheimer's Society, UK,  
317 Alzheimer's association, US, Medical Research Council, UK, Novo Nordisk, Piramal Life Sciences and GE  
318 Healthcare. P.M.M. gratefully acknowledges generous support from Edmond J Safra Foundation and Lily Safra,  
319 the NIHR Investigator programme and the UK Dementia Research Institute.

320

### 321 **Conflicts of Interest**

322 P.E. is a consultant to Roche, Pfizer and Novo Nordisk. He has received speaker fees from Novo Nordisk, Pfizer,  
323 Nordea, Piramal Life Science. He has received educational and research grants from GE Healthcare, Novo  
324 Nordisk, Piramal Life Science/Life Molecular Imaging, Avid Radiopharmaceuticals and Eli Lilly. He is an  
325 external consultant to Novo Nordisk and a member of their Scientific Advisory Board. P.M.M. acknowledges  
326 consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or  
327 speakers' honoraria from Novartis, Biogen and Roche and has received research or educational funds from  
328 Biogen, Novartis, GlaxoSmithKline and Nodthera.

329

330

331 **References**

332

333 1. Vasile F, Dossi E, Rouach N. Human astrocytes: structure and functions in the healthy brain.  
334 2017.

335

336 2. González-Reyes RE, Nava-Mesa MO, Vargas-Sánchez K, Ariza-Salamanca D, Mora-Muñoz L.  
337 Involvement of astrocytes in Alzheimer's disease from a neuroinflammatory and oxidative  
338 stress perspective. 2017.

339

340 3. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A $\beta$ 42  
341 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. *Brain Research* 2003.

342

343 4. Ries M, Sastre M. Mechanisms of A $\beta$  clearance and degradation by glial cells. 2016.

344

345 5. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. 2007.

346

347 6. Verkhatsky A, Rodrigues JJ, Pivoriunas A, Zorec R, Semyanov A. Astroglial atrophy in  
348 Alzheimer's disease. 2019.

349

350 7. Verkhatsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer's  
351 Disease. *Neurotherapeutics* 2010.

352

353 8. Márquez F, Yassa MA. Neuroimaging Biomarkers for Alzheimer's Disease. 2019.

354

355 9. Diniz LP, Tortelli V, Matias I, Morgado J, Araujo APB, Melo HM *et al.* Astrocyte transforming  
356 growth factor beta 1 protects synapses against A $\beta$  oligomers in Alzheimer's disease model.  
357 *Journal of Neuroscience* 2017.

358

359 10. Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: Focus on Astrocyte-neuron  
360 metabolic cooperation. 2011.

361

362 11. Regunathan S, Feinstein DL, Reis DJ. Expression of non-adrenergic imidazoline sites in rat  
363 cerebral cortical astrocytes. *Journal of Neuroscience Research* 1993.

364

365 12. Venkataraman AV, Keat N, Myers JF, Turton S, Mick I, Gunn RN *et al.* First evaluation of PET-  
366 based human biodistribution and radiation dosimetry of <sup>11</sup>C-BU99008, a tracer for imaging  
367 the imidazoline2 binding site. *EJNMMI Research* 2018.

368

369 13. Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J *et al.* Evaluation of <sup>11</sup>C-  
370 BU99008, a PET Ligand for the Imidazoline2 binding site in human brain. *Journal of Nuclear*  
371 *Medicine* 2018.

372

373 14. Tyacke RJ, Fisher A, Robinson ESJ, Grundt P, Turner EM, Husbands SM *et al.* Evaluation and  
374 initial in vitro and ex vivo characterization of the potential positron emission tomography

- 375 ligand, BU99008 (2-(4,5-Dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline  
376 2 binding site. *Synapse* 2012.
- 377
- 378 15. Parker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D *et al.* Evaluation of 11C-BU99008, a  
379 PET Ligand for the Imidazoline 2 Binding Sites in Rhesus Brain. *Journal of Nuclear Medicine*  
380 2014.
- 381
- 382 16. Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ *et al.* Imaging  
383 imidazoline-I2 binding sites in porcine brain using 11C-BU99008. *Journal of Nuclear Medicine*  
384 2013.
- 385
- 386 17. Kawamura K, Shimoda Y, Yui J, Zhang Y, Yamasaki T, Wakizaka H *et al.* A useful PET probe  
387 [11C]BU99008 with ultra-high specific radioactivity for small animal PET imaging of I2-  
388 imidazoline receptors in the hypothalamus. *Nuclear Medicine and Biology* 2017.
- 389
- 390 18. Calsolaro VM, P.M; Donat, C.K; Livingston, N.R.; Femminella, G.D.; Silva Guedes, S.; Myers, J.;  
391 Fan, Z.; Tyacke, R.J.; Venkataraman, A.V.; Perneczky, R.; Gunn, R.N.; Rabiner, E.A.;  
392 Gentleman, S.; Parker, C.A.; Murphy, P.S.; Wren, P.B.; Hinz, R.; Sastre, M.; Nutt, D.J.; Edison,  
393 P. Astrocyte reactivity with late onset cognitive impairment assessed in vivo using 11C-  
394 BU99008 PET and its relationship with amyloid load. *Molecular Psychiatry* (Accepted/In  
395 Press).
- 396
- 397 19. Wilson H, Dervenoulas G, Pagano G, Tyacke RJ, Polychronis S, Myers J *et al.* Imidazoline 2  
398 binding sites reflecting astroglia pathology in Parkinson's disease: An in vivo 11C-BU99008  
399 PET study. *Brain* 2019.
- 400
- 401 20. Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B *et al.* Evidence for astrocytosis  
402 in prodromal alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET  
403 paradigm combining 11C-Pittsburgh compound B and 18F-FDG. *Journal of Nuclear Medicine*  
404 2012.
- 405
- 406 21. Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte Biomarkers  
407 in Alzheimer's Disease. *Trends Mol Med* 2019; **25**(2): 77-95.
- 408
- 409 22. Kumar A, Koistinen NA, Malarte ML, Nennesmo I, Ingelsson M, Ghetti B *et al.* Astroglial  
410 tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. *Mol Psychiatry*  
411 2021.
- 412
- 413 23. Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H *et al.* Optimized classification  
414 of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach  
415 and comparison to visual assessment. *NeuroImage: Clinical* 2017.
- 416
- 417 24. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage* 2007; **38**(1): 95-  
418 113.
- 419

- 420 25. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L *et al.* Three-dimensional  
421 maximum probability atlas of the human brain, with particular reference to the temporal  
422 lobe. *Human Brain Mapping* 2003.
- 423
- 424 26. Gousias IS, Rueckert D, Heckemann RA, Dyet LE, Boardman JP, Edwards AD *et al.* Automatic  
425 segmentation of brain MRIs of 2-year-olds into 83 regions of interest. *NeuroImage* 2008.
- 426
- 427 27. Casanova R, Srikanth R, Baer A, Laurienti PJ, Burdette JH, Hayasaka S *et al.* Biological  
428 parametric mapping: A statistical toolbox for multimodality brain image analysis.  
429 *NeuroImage* 2007.
- 430
- 431 28. Ruiz J, Martín I, Callado LF, Meana JJ, Barturen F, García-Sevilla JA. Non-adrenoceptor  
432 [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from  
433 patients with Alzheimer's disease. *Neuroscience Letters* 1993.
- 434
- 435 29. Li JX. Imidazoline I2 receptors: An update. 2017.
- 436
- 437 30. Sastre M, Garcia-Sevilla JA. Opposite Age-Dependent Changes of  $\alpha$ 2A-Adrenoceptors and  
438 Nonadrenoceptor [3H]Idazoxan Binding Sites (I2-Imidazoline Sites) in the Human Brain:  
439 Strong Correlation of I2 with Monoamine Oxidase-B Sites. *Journal of Neurochemistry* 1993.
- 440
- 441 31. García-Sevilla JA, Escribá PV, Walzer C, Bouras C, Guimón J. Imidazoline receptor proteins in  
442 brains of patients with Alzheimer's disease. *Neuroscience Letters* 1998.
- 443
- 444 32. Santillo AF, Gambini JP, Lannfelt L, Långström B, Ulla-Marja L, Kilander L *et al.* In vivo imaging  
445 of astrocytosis in Alzheimer's disease: An 11C-L-deuteriodeprenyl and PIB PET study.  
446 *European Journal of Nuclear Medicine and Molecular Imaging* 2011.
- 447
- 448 33. Braak H, Del Trecidi K. Neuroanatomy and pathology of sporadic Alzheimer's disease. *Adv*  
449 *Anat Embryol Cell Biol* 2015; **215**: 1-162.
- 450
- 451 34. Scholl M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S *et al.* Early  
452 astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer  
453 positron emission tomography. *Sci Rep* 2015; **5**: 16404.
- 454
- 455 35. Zhang X, Fu Z, Meng L, He M, Zhang Z. The Early Events That Initiate beta-Amyloid  
456 Aggregation in Alzheimer's Disease. *Front Aging Neurosci* 2018; **10**: 359.
- 457
- 458 36. Olsen M, Aguilar X, Sehlin D, Fang XT, Antoni G, Erlandsson A *et al.* Astroglial Responses to  
459 Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease. *Molecular Imaging and*  
460 *Biology* 2018.
- 461
- 462 37. Wang Q, Wu J, Rowan MJ, Anwyl R.  $\beta$ -amyloid inhibition of long-term potentiation is  
463 mediated via tumor necrosis factor. *European Journal of Neuroscience* 2005.

- 464  
465 38. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose  
466 metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. *Neuron*  
467 2003.
- 468  
469 39. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE. Evidence for Apoptotic Cell Death in  
470 Alzheimer's Disease. *Experimental Neurology* 1995.
- 471  
472 40. Garaschuk O, Verkhratsky A. GABAergic astrocytes in Alzheimer's disease. 2019.
- 473  
474 41. Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M *et al.* Diverging  
475 longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's  
476 disease. *Brain* 2016.
- 477  
478 42. Rodriguez-Vieitez E, Ni R, Gulyas B, Toth M, Haggkvist J, Halldin C *et al.* Astrocytosis precedes  
479 amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative  
480 positron emission tomography and in vitro imaging study. *Eur J Nucl Med Mol Imaging* 2015;  
481 **42(7): 1119-1132.**
- 482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493




494 **Figure legends**

495 **Figure 1: Statistical Parametric Mapping (SPM) group analysis in patients compared to healthy controls**


496 **(a)** Increased  $^{11}\text{C}$ -BU99008 uptake in A $\beta$ -positive patients compared to healthy controls, rendered at cluster  
497 threshold of  $p < 0.05$  and an extent threshold of 50 voxels. **(b)** Decreased  $^{18}\text{F}$ -FDG uptake in A $\beta$ -positive patients  
498 compared to health controls, rendered at cluster threshold of  $p < 0.001$  and an extent threshold of 50 voxels. **(c)**  
499 Decreased grey matter volume in A $\beta$ -positive patients compared to healthy controls, rendered at cluster threshold  
500 of  $p < 0.05$  and an extent threshold of 50 voxels. **(d)** Increased  $^{18}\text{F}$ -Florbetaben uptake in all patients compared to  
501 healthy controls, rendered at cluster threshold of  $p < 0.001$  and an extent threshold of 50 voxels. Colourbar units  
502 are contrast estimates.

**(a)**

**Increased  $^{11}\text{C}$ -BU99008 uptake in  $\text{A}\beta$ +ve patients**

**(b)**


**Decreased  $^{18}\text{F}$ -FDG uptake in  $\text{A}\beta$ +ve patients**

**(c)**

**Decreased grey matter volume in  $\text{A}\beta$ +ve patients**

<https://doi.org/10.1101/2021.05.10.21261690>  
(which was not certified by peer review)

CC-BY-ND 4.0 International license

**(d)**

**Increased  $^{18}\text{F}$ -florbetaben uptake in all patients**

